NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01093196,"Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients",https://clinicaltrials.gov/study/NCT01093196,,COMPLETED,"This is a multicenter, randomized, controlled, 3 arm parallel group study designed to evaluate the efficacy and safety of three all-oral combinations: lenalidomide with dexamethasone (Rd) in comparison with lenalidomide in association with MP (MPR) and lenalidomide in association with cyclophosphamide - prednisone (CPR) in newly diagnosed symptomatic MM patients. This protocol also provides a substudy designed to observe asymptomatic patients excluded to the protocol that in any case could be inserted in the study.",NO,Multiple Myeloma,"DRUG: Melphalan, Prednisone, Lenalidomide|DRUG: Cyclophosphamide, Prednisone, Lenalidomide|DRUG: Lenalidomide, dexamethasone","Progression Free Survival, 5 years","Overall Survival, 5 years|Overall Response Rate, 5 years|Time to progression, 5 years|Time and duration of response, 5 years|Time to next therapy, 5 years|Grade 3-4 hematological and non-hematological adverse events (AEs), 5 years|Prognosis and cytogenetic abnormalities, 5 years",,Fondazione EMN Italy Onlus,,ALL,"ADULT, OLDER_ADULT",PHASE3,660,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EMN01,2009-10,2012-11,2024-07-01,2010-03-25,,2024-11-07,"Division Of Hematology, A.O.U. Citt√† della Salute e della Scienza di Torino, Torino, TO, 10126, Italy",
